Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus
AssigneeSungkyunkwan University Foundation for Corporate Collaboration
InventorsHyun-Ju Park, So-Jung Park, Yang-Gyun Kim
Life of this patent
Estimating the term…
Abstract
Provided is a homopiperazine compound for inhibiting ribosomal frameshifting by binding to an RNA pseudoknot structure of SARS coronavirus. Particularly, the present invention provides a pharmaceutical composition for inhibiting synthesis of protein induced by −1 frameshifting by binding to an RNA pseudoknot structure specifically existing in SARS coronavirus. The composition includes a therapeutically effective amount of homopiperazine compound of following chemical formula 1 or a pharmaceutically accepted salt thereof, and a pharmaceutically accepted carrier or excipient.
Claims8
A pharmaceutical composition for inhibiting synthesis of protein induced by -1 frameshifting by binding to an RNA pseudoknot structure specifically existing in SARS coronavirus, comprising:
- a therapeutically effective amount of a homopiperazine compound of the following chemical formula 2 or a pharmaceutically accepted salt thereof, and a pharmaceutically accepted carrier or excipient:
A pharmaceutical composition for antiviral treatment of virus-induced diseases, comprising:
- a therapeutically effective amount of homopiperazine compound of the following chemical formula 2 or a pharmaceutically accepted salt thereof, and a pharmaceutically accepted carrier or excipient
A compound having the following name:
- 2-((4-(2-methyl-thiazole-4-ylmethyl)-[1,4]diazepene-1-carbonyl)amino)benzoic acid ethyl ester.
Dependencies are inferred from the claim text.